Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.0
4.5
Journals
Cancers
Special Issues
Neoadjuvant Treatments in Breast Cancer Patients
share announcement

Neoadjuvant Treatments in Breast Cancer Patients

A special issue of Cancers (ISSN 2072-6694).

Deadline for manuscript submissions: closed (1 July 2021) | Viewed by 15171

Special Issue Editors

Dr. Laura Pizzuti

E-Mail Website
Guest Editor
Division of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Roma, Italy
Interests: breast cancer; HER2 signaling; target therapy; neoadjuvant treatments
Dr. Maddalena Barba

E-Mail Website
Guest Editor
Division of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Roma, Italy
Interests: breast cancer; target therapy; neoadjuvant treatments; systematic reviews; meta-analysis; coagulation; metabolism

Special Issue Information

Dear Colleagues,

Neoadjuvant therapy is the mainstay of treatment for locally advanced breast cancer. It provides an increasingly appealing alternative to the surgical approach in patients with primary operable disease.

Of note, neoadjuvant treatment may represent an adequate alternative for surgical de-escalation in patients suitable for complete resection at initial diagnosis. In this context, neoadjuvant therapy could lead to the conversion from mastectomy to breast-conserving therapies, reduce volume resection in breast-conserving surgery, and allow for a minimally invasive axillary management.

More recently, neoadjuvant strategies have gained additional strengths. The available armamentarium has considerably widened through the use of innovative, highly efficacious drugs, such as taxanes, dual anti-Her-2 blockade, and immunotherapy. Refined oncoplastic techniques have increased breast operability and allowed for aesthetic results to be achieved which increasingly meet our patients’ needs. In addition, the neoadjuvant setting provides an optimal milieu for molecular profiling, which could be used to gauge optimal responses through the use of tissue and/or serum biomarkers. The integrative use of sophisticated imaging techniques monitors and assesses breast and axillary responses to the neoadjuvant treatment. Lastly, though no less important, the accurate localisation of the primary tumour and involved axillary nodes increasingly enables safe de-escalation of surgery.

Dr. Laura Pizzuti
Dr. Maddalena Barba
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • neo-adjuvant therapy
  • locally advanced breast cancer
  • surgical de-escalation
  • minimally invasive axillary management
  • predictive/prognostic biomarkers

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

19 pages, 1981 KiB  
Article
Neoadjuvant Chemotherapy of Triple-Negative Breast Cancer: Evaluation of Early Clinical Response, Pathological Complete Response Rates, and Addition of Platinum Salts Benefit Based on Real-World Evidence
by Milos Holanek, Iveta Selingerova, Ondrej Bilek, Tomas Kazda, Pavel Fabian, Lenka Foretova, Maria Zvarikova, Radka Obermannova, Ivana Kolouskova, Oldrich Coufal, Katarina Petrakova, Marek Svoboda and Alexandr Poprach
Cancers 2021, 13(7), 1586; https://doi.org/10.3390/cancers13071586 - 30 Mar 2021
Cited by 17 | Viewed by 7381
Abstract
Pathological complete response (pCR) achievement is undoubtedly the essential goal of neoadjuvant therapy for breast cancer, directly affecting survival endpoints. This retrospective study of 237 triple-negative breast cancer (TNBC) patients with a median follow-up of 36 months evaluated the role of adding platinum [...] Read more.
Pathological complete response (pCR) achievement is undoubtedly the essential goal of neoadjuvant therapy for breast cancer, directly affecting survival endpoints. This retrospective study of 237 triple-negative breast cancer (TNBC) patients with a median follow-up of 36 months evaluated the role of adding platinum salts into standard neoadjuvant chemotherapy (NACT). After the initial four standard NACT cycles, early clinical response (ECR) was assessed and used to identify tumors and patients generally sensitive to NACT. BRCA1/2 mutation, smaller unifocal tumors, and Ki-67 ≥ 65% were independent predictors of ECR. The total pCR rate was 41%, the achievement of pCR was strongly associated with ECR (OR = 15.1, p < 0.001). According to multivariable analysis, the significant benefit of platinum NACT was observed in early responders ≥45 years, Ki-67 ≥ 65% and persisted lymph node involvement regardless of BRCA1/2 status. Early responders with pCR had a longer time to death (HR = 0.28, p < 0.001) and relapse (HR = 0.26, p < 0.001). The pCR was achieved in only 7% of non-responders. However, platinum salts favored non-responders’ survival outcomes without statistical significance. Toxicity was significantly often observed in patients with platinum NACT (p = 0.003) but not for grade 3/4 (p = 0.155). These results based on real-world evidence point to the usability of ECR in NACT management, especially focusing on the benefit of platinum salts. Full article
(This article belongs to the Special Issue Neoadjuvant Treatments in Breast Cancer Patients)
►▼ Show Figures

Graphical abstract

13 pages, 506 KiB  
Article
Neoadjuvant Immune-Checkpoint Blockade in Triple-Negative Breast Cancer: Current Evidence and Literature-Based Meta-Analysis of Randomized Trials
by Daniele Marinelli, Marco Mazzotta, Laura Pizzuti, Eriseld Krasniqi, Teresa Gamucci, Clara Natoli, Antonino Grassadonia, Nicola Tinari, Silverio Tomao, Isabella Sperduti, Giuseppe Sanguineti, Andrea Botticelli, Agnese Fabbri, Claudio Botti, Gennaro Ciliberto, Maddalena Barba and Patrizia Vici
Cancers 2020, 12(9), 2497; https://doi.org/10.3390/cancers12092497 - 3 Sep 2020
Cited by 15 | Viewed by 3321
Abstract
Chemotherapy based on the sequential use of anthracyclines and taxanes has long represented the most efficacious approach in the management of early-stage, triple-negative breast cancer, whose aggressive behavior is widely renowned. This standard chemotherapy backbone was subsequently enriched by the use of carboplatin, [...] Read more.
Chemotherapy based on the sequential use of anthracyclines and taxanes has long represented the most efficacious approach in the management of early-stage, triple-negative breast cancer, whose aggressive behavior is widely renowned. This standard chemotherapy backbone was subsequently enriched by the use of carboplatin, based on its association with increased pathologic complete response and efficacy in the metastatic setting. Following the results from the IMpassion130 trial, the recent approval of the immunotherapic agent atezolizumab in combination with chemotherapy as first-line treatment for programmed-death ligand 1-positive, unresectable locally advanced, or metastatic triple-negative breast cancer increasingly fueled the flourishing of trials of immune-checkpoint inhibitors in the early setting. In this work, we review the most recent inherent literature in light of key methodological issues and provide a quantitative summary of the results from phase II–III randomized trials of immunotherapic agents combined with chemotherapy in the setting of interest. Hints regarding future directions are also discussed. Full article
(This article belongs to the Special Issue Neoadjuvant Treatments in Breast Cancer Patients)
►▼ Show Figures

Figure 1

Review

Jump to: Research

18 pages, 2966 KiB  
Review
Options to Determine Pathological Response of Axillary Lymph Node Metastasis after Neoadjuvant Chemotherapy in Advanced Breast Cancer
by Vijayashree Murthy, Jessica Young, Yoshihisa Tokumaru, Marie Quinn, Stephen B. Edge and Kazuaki Takabe
Cancers 2021, 13(16), 4167; https://doi.org/10.3390/cancers13164167 - 19 Aug 2021
Cited by 8 | Viewed by 3786
Abstract
Increasing use of neoadjuvant therapy in large tumors or node positive disease in breast cancer patients or hormone negative and HER 2 overexpressing cancers often gives rise to complete clinical response, with resolution of disease in the breast and axilla. These results have [...] Read more.
Increasing use of neoadjuvant therapy in large tumors or node positive disease in breast cancer patients or hormone negative and HER 2 overexpressing cancers often gives rise to complete clinical response, with resolution of disease in the breast and axilla. These results have raised important questions to deescalate loco-regional surgical treatment options with minimum recurrence risk and treatment related morbidity. Although there is excellent prognosis following clinical response, the primary goal of surgery still remains to confirm complete pathological response in the biopsied node that was previously positive and now clinically/radiologically negative (ycN0). Biopsied lymph nodes are often marked with a clip to allow future identification at the time of definitive surgery. The goal of lymph node surgery in oncology is that it should be accurate, hence the significance of localizing the biopsied node. This article aims to review the different options to localize the deemed positive node at the time of definitive surgery, in order to help determine pathological response after neoadjuvant therapy. Full article
(This article belongs to the Special Issue Neoadjuvant Treatments in Breast Cancer Patients)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop